- Company
- Wet AMD tx new option to shorten Eyelea's minimum cycle
- by May 16, 2022 06:13am
- Bayer's macular degeneration treatment Eyelea took the lead in establishing an optimized treatment strategy for patients by shortening the minimum treatment cycle. It is evaluated that a new option was presented in macular degeneration treatment that determines the treatment cycle according to the patient's condition. According to the phar
- Company
- Bio Clusters gather to compete at BIO Korea 2022
- by Kim, Jin-Gu May 13, 2022 05:46am
- Major Bio Clusters of local governments have gathered in one place. Major Bio Clusters of local governments including Osong, Incheon, Hongneung, Gimhae, Wonju, and Daejeon municipalities as well as the event’s co-host Chungcheongbuk-do are in heated competition to promote their cluster in the ‘BIO KOREA 2022’ event that is being held f
- Company
- Lumakras is a new opportunity for lung cancer patients
- by May 13, 2022 05:45am
- "Lumakras is the first-in-class and best-in-class for patients with KRAS G12C mutated non-small cell lung cancer who failed existing treatment. The reliability of drugs has also increased over the past two years with long-term data, and it is expected that they may be used in combination with other drugs such as immuno-cancer drugs in the future
- Company
- LG Chem’s partner enters Phase I trial on its immunotherapy
- by Kim, Jin-Gu May 13, 2022 05:45am
- On the 12th, Cue Biopharma, LG Chem’s partner in developing a cancer immunotherapy, announced it had won FDA approval to initiate Phase 1 clinical trials for ‘CUE-102 .’ LG Chem has exclusive rights to develop and market the candidate in 11 Asian countries including Korea, China, and Japan. With the trial approval, Cue Biopharma wil
- Company
- K-Cab & Fexuclu are quickly targeting the global market
- by Chon, Seung-Hyun May 12, 2022 06:07am
- New drug products developed by domestic pharmaceutical companies with their own technologies are accelerating their targeting in the global market. However, some point out that it is difficult to predict commercial success because there are many variables such as the situation of the local market even if they have reserved to enter the overse
- Company
- 17 are immuno-cancer drugs out of 111 KDDF support projects
- by Kim, Jin-Gu May 12, 2022 06:06am
- Of the 111 KDDF support tasks selected by the government last year, 17 are confirmed to be immuno-cancer drugs. Kim Soon-nam, head of KDDF R&D, who is leading the project, predicted, "In the future, R&D tasks related to immuno-cancer drugs will increase further." Kim Soon-nam, head of the headquarters, attended a session under the theme of
- Company
- GLPharmtech has obtained approval IMD for Janumet XR
- by Nho, Byung Chul May 12, 2022 06:06am
- (CEO Wang Hoon-sik) announced on the 11th that it has obtained an item approval from the Ministry of Food and Drug Safety for a new salt-improving drug of Janumet XR (Sitagliptin Phosphate+ Metformin Hydrochloride. GLPharmtech items licensed this time adopted Sitagliptin, a modified salt drug for Chong Kun Dang Sitaformin XR/Hanmi Pharmace
- Company
- Will Luxturna be reimbursed by the end of this year?
- by Eo, Yun-Ho May 11, 2022 05:56am
- Attention is focusing on the procedure for registering insurance benefits for another one-shot gene therapy. According to related industries, discussions are underway to register the benefit of Novartis' Inherited Retinal Dystrophy (IRD) treatment Luxturna. As the application for benefits was submitted in September last year, it remains to
- Company
- Domestic COVID-19 vaccine developers at a crossroads
- by Kim, Jin-Gu May 11, 2022 05:55am
- HK Inno. N announced it will voluntarily discontinue the development of its COVID-19 vaccine due to the sudden change in the spread of COVID-19 in Korea. With the marketing approval of SK Bioscience’s COVID-19 vaccine imminent, the indecisiveness among the other vaccine developers in Korea is increasing According to industry sources o
- Company
- Kakao is throwing the hat into the healthcare business
- by Kim, Jin-Gu May 10, 2022 06:14pm
- Large domestic companies are throwing their hat into the healthcare business. In the past year, leading conglomerates such as Lotte, Kakao, Doosan, Hyundai Heavy Industries & Construction, GS, CJ, and OCI have formalized their entry into the healthcare market. Analysts say that Samsung and SK have succeeded in the pharmaceutical bio business
